Interestingly, in the 2014 Ozdemir et al. study in which α-SMA CAF ablation drives more aggressive PDAC growth, tumours were also rendered more sensitive to anti-CTLA4 immunotherapy, perhaps indicating distinct tumour-restraining and immune-suppressive roles for overlapping CAF populations. Here, CTLA4 is linked to neoplasm.